factual

Genome-engineering spinoffs as primary business value

Colossal's primary business driver is spinning out genome-engineering technology companies—two already spun off, two more in process—which Lamm believes are worth tens of billions of dollars because no one else has matched their capabilities, validated by feedback from healthcare investors like In-Q-Tel.

factualpending

Speaker

Ben Lamm

Evidence Quote

“Just our genome engineering technologies, we think, are worth tens of billions of dollars”

Source

394 - Bringing Back The Mammoth— Making Sense with Sam Harris
Created: 6/14/2026, 1:46:37 AM

Your notes

Loading notes...